Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration - Marketscreener.com

1 year ago 66

Homepage Equities China Shanghai Stock Exchange Jiangsu Kanion Pharmaceutical Co.,Ltd. News Summary     600557   CNE000001CL7 (600557) Add to my list   Report End-of-day punctuation Shanghai Stock Exchange  -  2022-12-28 18.83 CNY   +7.60% 03:00a Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration MT 10/09 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI 08/31 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Other languages Press Releases Official Publications Sector news 12/30/2022 | 03:00am EST MT Newswires 2022 All quality about JIANGSU KANION PHARMACEUTICAL CO.,LTD. 03:00a Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registrati.. MT 10/09 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months End.. CI 08/31 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended.. CI 04/11 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter E.. CI 03/03 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended.. CI 2021 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months End.. CI 2021 Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended.. CI 2021 Tranche Update connected Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announce.. CI 2021 Jiangsu Kanion Pharmaceutical Co.,Ltd’s Equity Buyback announced connected February 6, 2021 ha.. CI 2021 Tranche Update connected Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announce.. CI Financials Sales 2022 4 529 M 650 M 650 M Net income 2022 411 M 59,0 M 59,0 M Net Debt 2022 - - - P/E ratio 2022 26,7x Yield 2022 - Capitalization 11 008 M 1 581 M 1 581 M Capi. / Sales 2022 2,43x Capi. / Sales 2023 1,98x Nbr of Employees - Free-Float 58,4% Chart JIANGSU KANION PHARMACEUTICAL CO.,LTD. Duration : Period : Technical investigation trends JIANGSU KANION PHARMACEUTICAL CO.,LTD. Short Term Mid-Term Long Term Trends Bearish Neutral Bullish Income Statement Evolution Consensus Sell Buy Mean consensus BUY Number of Analysts 2 Last Close Price 18,83 CNY Average people price 17,12 CNY Spread / Average Target -9,08% EPS Revisions Managers and Directors Wei Xiao Chairman & General Manager An Liang Xiao Financial Director Shi Hua Yin Chairman-Supervisory Board Zheng Yang Independent Director Qiang Dong Independent Director Sector and Competitors 1st jan. Capi. (M$) JIANGSU KANION PHARMACEUTICAL CO.,LTD. 53.84% 1 581 JOHNSON & JOHNSON 3.27% 464 228 ELI LILLY AND COMPANY 32.22% 348 734 NOVO NORDISK A/S 28.01% 304 761 PFIZER, INC. -13.97% 288 131 ABBVIE INC. 20.06% 287 387

1. Homepage
2. Health
3. Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration - Marketscreener.com